Long-Term Safety and Immunogenicity of an MF59-Adjuvanted Spike Glycoprotein-Clamp Vaccine for SARS-CoV-2 in Adults Aged 18–55 Years or ≥56 Years: 12-Month Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 1 Trial
Keith J. Chappell(Australian Research Council), Trent P. Munro(The University of Queensland), Julia Lackenby(The University of Queensland), Alberto A. Amarilla(Commonwealth Scientific and Industrial Research Organisation), Thi H. O. Nguyen(The University of Melbourne), Daniel Watterson(The University of Queensland), Luca Hensen(University Children's Hospital Tübingen), Benjamin Liang(The University of Queensland), Charani Ranasinghe(Australian National University), Zheyi Li(Australian National University), Danushka K. Wijesundara(The University of Queensland), Paul Griffin(The University of Queensland), Patrick C. Reading(Peter Doherty Institute), Peter Tapley(The University of Queensland), Paul R. Young(Kent State University), Kanta Subbarao(Peter Doherty Institute), James Barnes(Peter Doherty Institute), Francesca L. Mordant(The University of Melbourne), Wuji Zhang(The University of Melbourne), Naphak Modhiran(The University of Queensland), Katherine Kedzierska(Infectious Disease Research Institute), Mai Tran(Ajou University), Jillian Bennet
Cited by 0
Related Papers
Influenza
|Nature Reviews Disease Primers|2018|1.5k
A three-stage intrathymic development pathway for the mucosal-associated invariant T cell lineage
|Nature Immunology|2016|365
Lack of transmission of H5N1 avian–human reassortant influenza viruses in a ferret model
|Proceedings of the National Academy of Sciences|2006|347